摘要
目的研究噻唑烷二酮类药物罗格列酮对链脲佐菌素(STZ)诱导的糖尿病大鼠肾脏损害的保护作用。方法40只雄性SD大鼠随机分3组:即正常对照组(C组,n=10);糖尿病对照组(DC组,n=15),STZ 60 mg/kg腹腔注射;罗格列酮治疗组(DR组,n=15),4 mg.kg-1.d-1罗格列酮无菌水混悬液灌胃。10周后观察各组大鼠血糖(BG)、氧化血红蛋白(HbA1 c)、尿素氮(BUN)、尿微量白蛋白(MAU)等生化指标及光镜、电镜下肾脏病理形态学改变。结果DC组大鼠肾小球毛细血管狭窄甚至闭塞,基底膜显著增厚,系膜细胞明显增生;罗格列酮治疗后的DR组上述改变明显改善。DC组及DR组的BG、HbA1 c、MAU、BUN较C组明显升高(P<0.01);DR组与DC组相比,BG、HbA1 c无明显差异(P>0.05),BUN、MAU明显于低DC组(P<0.01)。结论罗格列酮能够改善或延缓糖尿病大鼠肾脏病理学损害,表明它对糖尿病肾脏损害具有一定的保护作用。
Objective To observe the effects of rosiglitazone on kidney damage in streptozotocin induced diabetic rats. Methods Forty male Sprague - Dawley rats were randomized into 3 groups： normal control rats （group C, n = 10）, diabetic rats （group DC, n = 15 ） and treated diabetic rats （group DR, n = 15 ）. The dibetes was induced with streptozotocin （STZ） 60 mg · kg^-1 ip; the diabetic rats were treated with axenic rosiglitazone 4 mg · kg^-1 in water by mouth qd. Blood glucose, HbAl c, BUN, microalbuminuria and kidney pathological changes were examined 10 weeks after treatment. Results The pathological changes of kidney in group DC included stenosis or occlusion of capillaries, proliferation of mesangial ceils and thickening of glomerular basement membrane; all of these changes got improved after treatment in group DR. The levels of urea nitrogen and microalbuminuria were significantly lower in group DR than in group DC, but still higher than in group C （P 〈 0.01 ）. Conclusion Rosiglitazone can improve or retard the nephropathology in diabetic rats, exerting certain protective effects on the kidney.
出处
《徐州医学院学报》
CAS
2007年第4期242-245,共4页
Acta Academiae Medicinae Xuzhou
